The U.S. Food and Drug Administration (FDA) has granted landmark approval to asundexian, making it the first-in-class factor XIa inhibitor cleared for secondary stroke prevention. Designed to be added alongside standard antiplatelet therapy, the medication offers patients a targeted new option for preventing recurrent ischemic strokes without significantly elevating major bleeding risks. Cardiovascular specialists hail the regulatory decision as a major step forward in precision thrombosis care for high-risk neurology and cardiology patients.
About the Author
